I for one would like them to sell, even at that $2.5-$3.0 per share, if they sell to a quality pharma that has resources to put into this endeavor. TCRT limps along with insufficient money to move anything quickly, and I think the anti-viral t-CRT has great promise -- I'd like to see it move forward quickly.
That said, I do believe if the next few patients show decent/good results, and I'm talking 5-8 patients (ten total), this stock will go over that $3 bucks, and potentially the company might sell then for double that or more. 250 million shares, at $3, is just $750 million which nothing for a pharma to shell out, this without TCRT showing definitively stellar results but just good results on say 40% of patients. And it would be real helpful to reduce the schedule from that 26 day turn-a-round to 10 days -- this is the kinda progress where you need good technical resources and money.
jack